Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lentinan

Drug Profile

Lentinan

Alternative Names: LC 33; YM 09222

Latest Information Update: 05 Jul 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ajinomoto
  • Developer Ajinomoto; EA Pharma; Taiho Pharmaceutical
  • Class Antineoplastics; Antivirals; Beta Glucans
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gastric cancer
  • No development reported Breast cancer; Colorectal cancer; HIV infections; Liver cancer; Lung cancer; Prostate cancer

Most Recent Events

  • 21 Jun 2017 EA Pharma decides to withdraw lentinan (IV, Injection) for the treatment of Gastric Cancer in Japan as the demand for the product has dropped
  • 30 Nov 2005 No development reported - Clinical-Phase-Unknown for Breast cancer in Japan (unspecified route)
  • 30 Nov 2005 No development reported - Clinical-Phase-Unknown for Colorectal cancer in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top